MedTrace Logo

Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome

NCT01613456 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 364

Last updated 2015-05-14

No results posted yet for this study

Summary

The main purpose of this study is the effect of the probiotic yeast Saccharomyces cerevisiae CNCM I-3856 on abdominal pain or intestinal discomfort in patients presenting with the irritable bowel syndrome (IBS)

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Saccharomyces cerevisiae CNCM I-3856

2 capsules/day during 12 weeks

DIETARY_SUPPLEMENT

Placebo

Capsule with comparable organoleptic properties and weight than the experimental product. 2 capsules/day during 12 weeks

Sponsors & Collaborators

  • BioFortis

    collaborator OTHER

  • University of Nottingham

    collaborator OTHER

  • Lesaffre International

    lead INDUSTRY

Principal Investigators

  • David GENDRE, MD · BioFortis

  • Robin SPILLER, Professor of Gastroenterology · Nottingham Digestive Diseases Centre University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613456 on ClinicalTrials.gov